Cat. No. 2146
Chemical Name: N,N''-1,4-Butanediylbis[N'-(3-isothiocyanatophenyl)thiourea
Biological ActivitySelective antagonist of P2Y6 nucleotide receptors; IC50 values are 37 and 98 nM at human and rat P2Y6 receptors respectively. Displays no activity at P2Y1, P2Y2, P2Y4 and P2Y11 receptors (IC50 > 10 μM). Inhibits agonist-induced cardiomyocyte contraction and UDP-induced phagocytosis.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Mamedova et al (2004) Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem.Pharmacol. 67 1763. PMID: 15081875.
Koizumi et al (2007) UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446 1091. PMID: 17410128.
Kukulski et al (2007) Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo. J.Leukoc.Biol. 81 1269. PMID: 17322022.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: MRS 2578, supplier, Selective, P2Y6, antagonists, Receptors, Purinergic, purinoceptors, MRS2578
Find multiple products by catalog number
New Products in this Area
GPR35 agonist; more potent than zaprinast (Cat. No. 0947)H2L 5765834
LPA1,3,5 antagonistCYM 50308
Potent and selective S1P4 agonistH2L5186303
Potent and selective LPA2 receptor antagonistMEDICA 16
FFA1 (GPR40) agonist. Also inhibits ATP citrate lyaseBX 471
Potent, selective CCR1 antagonistPF 04418948
Potent and selective EP2 receptor antagonistLatanoprost
FP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptorsGRI 977143
Selective LPA2 receptor non-lipid agonistCYM 50260
Potent and selective S1P4 agonistG-36
Selective GPR30 antagonistStrontium chloride
Calcium sensing receptor (CaSR) agonistCS 2100
Selective S1P1 agonistSMANT hydrochloride
Inhibits Smoothened (Smo) accumulationTUG 891
Potent and selective GPR120 agonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.